66 Biggest Movers From Yesterday
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
Why Virpax Pharmaceuticals Shares Are Soaring Today
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) is surging higher Tuesday after the company announced that it received a written pre-investigational new drug response from the U.S. Food and Drug Administration for MMS019.
Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; Virpax Pharmaceuticals Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.18% to 35,204.03 while the NASDAQ fell 1.24% to 14,610.77. The S&P also fell, dropping 1.06% to 4,432.01.
Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge
Midway through trading Tuesday, the Dow traded down 0.81% to 35,336.88 while the NASDAQ fell 0.89% to 14,661.86. The S&P also fell, dropping 0.65% to 4,450.54.
48 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
Mid-Morning Market Update: Markets Open Lower; Walmart Profit Tops Estimates
Following the market opening Tuesday, the Dow traded down 0.67% to 35,385.44 while the NASDAQ fell 0.79% to 14,676.74. The S&P also fell, dropping 0.54% to 4,455.32.
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs.
Why Virpax Pharmaceuticals Stock Flying Higher?
Virpax Pharmaceuticals Inc (NASDAQ:VRPX) has received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019. The drug candidate…
Virpax Pharma Reports Received FDA Response, Guidance On Its MMS019: ‘Company to Pursue Prophylactic Treatment Against SARS and Influenza for Daily Use as an OTC Product’
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today